Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP)

5.96
Delayed Data
As of 3:59pm ET
 +0.47 / +8.56%
Today’s Change
4.56
Today|||52-Week Range
14.93
-28.28%
Year-to-Date
Ziopharm Co-Dependency Spirals Down in Amended Intrexon Deal
Jun 30 / TheStreet.com - Paid Partner Content
Better Buy: Ziopharm Oncology, Inc. vs. Celgene
Jun 18 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close5.49
Today’s open5.43
Day’s range5.40 - 5.96
Volume2,662,203
Average volume (3 months)2,557,056
Market cap$723.8M
Dividend yield--
Data as of 3:59pm ET, 07/01/2016

Growth & Valuation

Earnings growth (last year)-209.68%
Earnings growth (this year)+55.56%
Earnings growth (next 5 years)--
Revenue growth (last year)+215.51%
P/E ratioNM
Price/Sales240.58
Price/Book8.28

Competitors

 Today’s
change
Today’s
% change
AMPHAmphastar Pharmaceut...+0.16+0.99%
ADROAduro Biotech Inc+0.93+8.22%
KERXKeryx Biopharmaceuti...+0.18+2.72%
FOLDAmicus Therapeutics ...+0.28+5.13%
Data as of 4:00pm ET, 07/01/2016

Financials

Next reporting dateAugust 4, 2016
EPS forecast (this quarter)-$0.11
Annual revenue (last year)$4.3M
Annual profit (last year)-$120.1M
Net profit margin-2,772.11%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Managing Director
Laurence James Neil Cooper
COO, Secretary, Chief Legal Officer &
Executive VP
Caesar J. Belbel
Corporate headquarters
Boston, Massachusetts

Forecasts

Partner Offers

Search for Jobs